Tissue factor dependent pathway and the diagnosis of pre-eclampsia

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 2, 2011, Pages 125-130

  Lwaleed, Bashir A ^a   Dusse, Luci ^b   Cooper, Alan J ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Coagulation; FVII; FVIIa; pre eclampsia; TF; TFPI

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE PREDISPOSITION; FETUS DEVELOPMENT; HEMOSTASIS; HUMAN; MATERNAL MORBIDITY; MATERNAL MORTALITY; PATHOGENESIS; PERINATAL MORBIDITY; PLACENTA PERFUSION; PREECLAMPSIA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THIRD TRIMESTER PREGNANCY;

BIOLOGICAL MARKERS; FACTOR VII; FEMALE; HEMOSTASIS; HUMANS; LIPOPROTEINS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, THIRD; SENSITIVITY AND SPECIFICITY; THROMBOPLASTIN;

EID: 79952304277     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1270338     Document Type: Article

References (55)

1. Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity: case-control study. BMJ 2001 322 7294 1089-1093 discussion 1093-1094 (Pubitemid 32411179)
2. National Institute for Health and Clinical Excellence. Antenatal Care: Routine Care for the Healthy Pregnant Woman. National Institute for Health and Clinical Excellence 2003
3. Villar J, Say L, Gülmezoglu A M. et al. Eclampsia and pre-eclampsia a worldwide health problem for 2000 years. In: Critchley H MacLean A Poston L Walker J eds. Pre-Eclampsia. London, United Kingdom RCOG Press 2003 189-207
4. Harrison M J., Kushner K E., Benzies K, Kimak C, Jacobs P, Mitchell B F. In-home nursing care for women with high-risk pregnancies: outcomes and cost. Obstet Gynecol 2001 97 6 982-987 (Pubitemid 32522498)
5. Turnbull D A., Wilkinson C, Gerard K et al. Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women. Lancet 2004 363 9415 1104-1109 (Pubitemid 38452782)
6. Simon J, Gray A, Duley L, Magpie Trial Collaborative Group. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG 2006 113 2 144-151
7. National High Blood Pressure Education Program Working Group Report on High Pressure in Pregnancy. National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 1990 163 5 Pt 1 1691-1712
8. Diagnosis and management of pre-eclampsia and eclampsia. Armenian Medical Network. 2003. Available at: http://www.health.am/gyneco/more/preeclampsia- eclampsia
9. Freeman D J., Tham K, Brown E A., Rumley A, Lowe G D., Greer I A. Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia. J Thromb Haemost 2008 6 3 421-427 (Pubitemid 351280108)
10. VanWijk M J., Boer K, Berckmans R J. et al. Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Thromb Haemost 2002 88 3 415-420 (Pubitemid 35021598)
11. Kobayashi T, Tokunaga N, Sugimura M et al. Coagulation/fibrinolysis disorder in patients with severe preeclampsia. Semin Thromb Hemost 1999 25 5 451-454 (Pubitemid 30010799)
12. Kruithof E K., Tran-Thang C, Gudinchet A et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987 69 2 460-466 (Pubitemid 17022014)
13. Estellés A, Gilabert J, Keeton M et al. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994 84 1 143-150 (Pubitemid 24193815)
14. Estellés A, Gilabert J, Aznar J, Loskutoff D J., Schleef R R. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989 74 4 1332-1338 (Pubitemid 19227444)
15. Djelmis J, Kendi S, Bukovi D, Pfeifer D, Ivanisevi M. The effect of coagulation parameters on the placental respiratory and nutritive function in women having chronic hypertension with superimposed preeclampsia. Coll Antropol 1997 21 1 127-137 (Pubitemid 127448679)
16. Bremme K, Blombäck M. Hemostatic abnormalities may predict chronic hypertension after preeclampsia. Gynecol Obstet Invest 1996 41 1 20-26 (Pubitemid 26021646)
17. Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset P M., WislØff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand 1999 78 3 191-197 (Pubitemid 29110281)
18. Savelieva G M., Efimov V S., Grishin V L., Shalina R I., Kashezheva A Z. Blood coagulation changes in pregnant women at risk of developing preeclampsia. Int J Gynaecol Obstet 1995 48 1 3-8
19. Kobayashi T, Sumimoto K, Tokunaga N et al. Coagulation index to distinguish severe preeclampsia from normal pregnancy. Semin Thromb Hemost 2002 28 6 495-500
20. Dusse L M., Carvalho M G., Getliffe K, Voegeli D, Cooper A J., Lwaleed B A. Increased circulating thrombomodulin levels in pre-eclampsia. Clin Chim Acta 2008 387 1-2 168-171 (Pubitemid 350050927)
21. Tanjung M T., Siddik H D., Hariman H, Koh S C. Coagulation and fibrinolysis in preeclampsia and neonates. Clin Appl Thromb Hemost 2005 11 4 467-473 (Pubitemid 41546775)
22. Vinnars M T., Wijnaendts L C., Westgren M, Bolte A C., Papadogiannakis N, Nasiell J. Severe preeclampsia with and without HELLP differ with regard to placental pathology. Hypertension 2008 51 5 1295-1299 (Pubitemid 351555940)
23. Øian P, Omsjø I, Maltau J M., Osterud B. Increased sensitivity to thromboplastin synthesis in blood monocytes from pre-eclamptic patients. Br J Obstet Gynaecol 1985 92 5 511-517 (Pubitemid 15095910)
24. Yamada N, Kido K, Hayashi S, Mukai M, Harbara H. An experimental model of toxemia of pregnancy in spontaneously hypertensive rats (SHR). Int J Biol Res Pregnancy 1981 2 2 58-62 (Pubitemid 11003148)
25. Brown M A. The physiology of pre-eclampsia. Clin Exp Pharmacol Physiol 1995 22 11 781-791
26. Howie P W., Begg C B., Purdie D W., Prentice C R. Use of coagulation tests to predict the clinical progress of pre-eclampsia. Lancet 1976 2 7981 323-325
27. Sandset P M., Hellgren M, Uvebrandt M, Bergström H. Extrinsic coagulation pathway inhibitor and heparin cofactor II during normal and hypertensive pregnancy. Thromb Res 1989 55 5 665-670 (Pubitemid 19248261)
28. Estellés A, Gilabert J, Grancha S et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost 1998 79 3 500-508 (Pubitemid 28120779)
29. Bellart J, Gilabert R, Anglès A et al. Tissue factor levels and high ratio of fibrinopeptide A: D-dimer as a measure of endothelial procoagulant disorder in pre-eclampsia. Br J Obstet Gynaecol 1999 106 6 594-597 (Pubitemid 29245593)
30. Erez O, Romero R, Hoppensteadt D et al. Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med 2008 21 12 855-869
31. Aharon A, Lanir N, Drugan A, Brenner B. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment. J Thromb Haemost 2005 3 10 2355-2357 (Pubitemid 41727221)
32. Abdel Gader A M., Al-Mishari A A., Awadalla S A., Buyuomi N M., Khashoggi T, Al-Hakeem M. Total and free tissue factor pathway inhibitor in pregnancy hypertension. Int J Gynaecol Obstet 2006 95 3 248-253 (Pubitemid 44715902)
33. Dusse L M., Carvalho M G., Getliffe K, Voegeli D, Cooper A J., Lwaleed B A. Total plasma tissue factor pathway inhibitor levels in pre-eclampsia. Clin Chim Acta 2008 388 1-2 230-232 (Pubitemid 350278587)
34. Hillman S, Chant I, Gu M, Rose P, Vatish M. Tissue pathway factor inhibitor (TFPI) activity is elevated in pregnant patients at 20 weeks gestation who subsequently develop preeclampsia. Thromb Haemost 2009 101 4 778-780
35. Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 1994 101 6 488-492 (Pubitemid 24210148)
36. Rousseau A, Favier R, Van Dreden P. Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: new and useful markers for pre-eclampsia? Eur J Obstet Gynecol Reprod Biol 2009 146 1 46-49
37. Villar J, Carroli G, Wojdyla D et al, World Health Organization Antenatal Care Trial Research Group. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol 2006 194 4 921-931
38. Grisaru-Granovsky S, Halevy T, Eidelman A, Elstein D, Samueloff A. Hypertensive disorders of pregnancy and the small for gestational age neonate: not a simple relationship. Am J Obstet Gynecol 2007 196 4 335, e1-e5
39. Chinni E, Colaizzo D, Tiscia G L. et al. Markers of haemostasis and angiogenesis in placentae from gestational vascular complications: impairment of mechanisms involved in maintaining intervillous blood flow. Thromb Res 2010 125 3 267-271
40. Ogawa M, Yanoma S, Nagashima Y et al. Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key. Placenta 2007 28 2-3 224-232 (Pubitemid 44914519)
41. Parry G C., Mackman N. Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain. J Clin Invest 2000 105 11 1547-1554 (Pubitemid 30390305)
42. Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost 2003 29 2 175-184
43. Palmier M O., Hall L J., Reisch C M., Baldwin M K., Wilson A G., Wun T C. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 1992 68 1 33-36
44. Donahue B S., Gailani D, Mast A E. Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass. J Thromb Haemost 2006 4 5 1011-1016
45. Moran P, Lindheimer M D., Davison J M. The renal response to preeclampsia. Semin Nephrol 2004 24 6 588-595 (Pubitemid 39505048)
46. Morris R H., Vassalli P, Beller F K., McCluskey R T. Immunofluorescent studies of renal biopsies in the diagnosis of toxemia of pregnancy. Obstet Gynecol 1964 24 32-46
47. Deng L, Bremme K, Hansson L O., Blombäck M. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia. Obstet Gynecol 1994 84 6 941-945 (Pubitemid 24360252)
48. Polliotti B M., Fry A G., Saller D N., Mooney R A., Cox C, Miller R K. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003 101 6 1266-1274 (Pubitemid 36694354)
49. Powers R W., Roberts J M., Cooper K M. et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005 193 1 185-191 (Pubitemid 40991843)
50. Unal E R., Robinson C J., Johnson D D., Chang E Y. Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. Am J Obstet Gynecol 2007 197 2 211, e1-e4
51. Redman C W., Denson K W., Beilin L J., Bolton F G., Stirrat G M. Factor-VIII consumption in pre-eclampsia. Lancet 1977 2 8051 1249-1252 (Pubitemid 8243369)
52. Meade T W., Miller G J., Rosenberg R D. Characteristics associated with the risk of arterial thrombosis and the pre-thrombotic state. In: Fuster V Verstraete M eds. Thrombosis in Cardiovascular Disorders. Philadelphia, PA WB Saunders 1992 79-97
53. Bremme K, Wramsby H, Andersson O, Wallin M, Blombäck M. Do lowered factor VII levels at extremely high endogenous oestradiol levels protect against thrombin formation? Blood Coagul Fibrinolysis 1994 5 2 205-210 (Pubitemid 24138054)
54. Greer I A., Haddad N G., Dawes J, Johnstone F D., Calder A A. Neutrophil activation in pregnancy-induced hypertension. Br J Obstet Gynaecol 1989 96 8 978-982 (Pubitemid 19209993)
55. Cignetti M, Garzetti G G., Marchegiani F, Fabris N, Romanini C. Natural killer cells and Tac antigen in the hypertension of pregnancy. Clin Exp Obstet Gynecol 1990 17 1 13-15 (Pubitemid 20230279)